Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis

Dayan CM, Daniels GH (1996) Chronic autoimmune thyroiditis. N Engl J Med 335:99–107 Mazziotti G, Sorvillo F, Naclerio C et al (2003) Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto’s thyroiditis. Eur J Endocrinol 148:383–388 Figueroa-Vega N, Alfonso-Pérez M, Benedicto I et al (2010) Increased circulating proinflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010(95):953–962 Skapenko A, Niedobitek GU, Kalden JR et al (2004) Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol 172:6427–6434 Marazuela M, García-López MA, Figueroa-Vega N et al (2006) Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab 91:3639–3646 Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167 Riesco-Eizaguirre G, Santisteban P (2007) New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer 14:957–977 Ozgen AG, Karadeniz M, Erdogan M et al (2009) The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32:491–494 Cunha LL, Aj Tincani, Assumpcao LV et al (2011) Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) 66:1203–1208 Simonovic SZ, Mihaljevic O, Majstorovic I et al (2015) Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 production before and reduced Th2 cytokine production after radioactive iodine therapy. Cancer Immunol Immunother 64:75–82 Stassi G, Todaro M, Zerilli M et al (2003) Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63:6784–6790 Jankovic B, Le KT, Hershman JM (2013) Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482 Weber F (2014) Lymphocytes and thyroid cancer: more to it than meets the eye? Endocr Relat Cancer 21:C1–C5 Cunha LL, Marcello MA, Ward LS (2014) The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocr Relat Cancer 21:R85–R103 Kashima K, Yokoyama S, Noguchi S et al (1998) Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 8:197–202 Singh B, Shaha AR, Trivedi H et al (1999) Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact of presentation, management and outcome. Surgery 126:1070–1077 Kim EY, Kim WG, Kim WB et al (2009) Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 71:581–586 Lee JH, Kim Y, Choi JW et al (2013) The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 168:343–349 Kebebew E, Treseler P, Ituarte P, Clark O (2001) Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 25:632–637 Cunha LL, Ward LS (2012) Concurrent lymphocytic thyroiditis is associated to less aggressive papillary thyroid carcinomas. Eur Arch Otorhinolaryngol 269:699–700 Schuetz M, Duan H, Wahl K et al (2006) T Lymphocyte cytokine production patterns in Hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Anticancer Res 26:4591–4596 Nikiforov YE (2012) Thyroid tumors: classification, staging, and general considerations. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Diagnostic pathology and molecular genetics of the thyroid, 2nd edn. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, pp 108–119 Budhu A, Wang XW (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80:1197–1213 Bodelon C, Polley MY, Kemp TJ et al (2013) Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol 24:2073–2079 Ellyard JI, Simson L, Parish CR (2007) Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 70:1–11 Mattes J, Hulett M, Xie W et al (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 197:387–393 Roy M, Chen H, Sippel RS (2013) Current understanding and management of medullary thyroid cancer. Oncologist 18:1093–1100 Schroder K, Hertzog PJ, Ravasi T et al (2004) Interferon-Υ: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189 Del Prete GF, Tiri A, Mariotti S et al (1987) Enhanced production of gamma-interferon by thyroid-derived T cell clones from patients with Hashimoto’s thyroiditis. Clin Exp Immunol 69:323–331 Zaidi MR, Merlino G (2011) The two faces of interferon-Υ in cancer. Clin Cancer Res 17:6118–6124 Miller CH, Maher SG, Young HA (2009) Clinical use of interferon-gamma. Ann N Y Acad Sci 1182:69–79 Hossain MS, Bhimani C, Zhengjia C et al (2011) Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients. [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2–6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 71(8 Suppl):Abstract nr 5525. doi:10.1158/1538-7445.AM2011-5525 Kang S, Tanaka T, Kishimoto T (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 27:21–29 Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40:1830–1835 Baki M, Akman FE, Vural P et al (2012) The combination of interleukin-10 -1082 and tumor necrosis factor α -308 or interleukin-6 -174 genes polymorphisms suggests an association with susceptibility to Hashimoto’s thyroiditis. Int Immunopharmacol 12:543–546 Weetman AP, Bright-Thomas R, Freeman M (1990) Regulation of interleukin-6 release by human thyrocytes. J Endocrinol 127:357–361 Ajjan RA, Watson PF, Weetman AP (1996) Cytokines and thyroid function. Adv Neuroimmunol 6:359–386 Ruggeri RM, Sciacchitano S, Vitale A et al (2009) Serum hepatocyte growth factor (HGF) is increased in Hashimoto’s thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals. J Endocrinol Invest 32:465–469 Sieminska L, Wojciechowska C, Kos-Kudla B et al (2010) Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto’s thyroiditis. Endokrynol Pol 61:112–116 Sehgal PB (1990) Interleukin 6 in infection and cancer. Proc Soc Exp Biol Med 195:183–191 Kura Y, De Velasco MA, Kobayashi Y, et al (2013) Interleukin-6 (IL-6) as a therapeutic target in prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 73(8 Suppl):Abstract nr 1226. doi:10.1158/1538-7445.AM2013-1226 Zhang Y, Yan W, Collins MA et al (2013) Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 73:6359–6374 Ujiie H, Tomida M, Akiyama H et al (2012) Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 32:3251–3258 Huang BY, Hseuh C, Chao TC et al (2011) Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 22:144–149 Ng TH, Britton GJ, Hill EV et al (2013) Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 4:129–140 Smilek DE, Ehlers MR, Nepom GT (2014) Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech 7:503–513 de Waal-Malefyt R, Yssel H, de Vries JE (1993) Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150:4754–4765 Cyktor JC, Turner J (2011) Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect Immunol 79:2964–2973 Franks AL, Slansky JE (2012) Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 32:1119–1136 Luheshi N, Davies GC, Poon E et al (2013) Th1 and Th2 cytokines determine how CD40 activation changes human macrophage function in vitro. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 73(8 Suppl):Abstract nr 1542. doi:10.1158/1538-7445.AM2013-1542 Becker JC, Andersen MH, Schrama D et al (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148 Atsumi T, Singh R, Sabharwal L et al (2014) Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 74:8–14 Murray JI, West NR, Murphy LC et al (2014) Intratumoral inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 22:R51–R67